Comparative Pharmacology
Head-to-head clinical analysis: BUTALAN versus NEMBUTAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTALAN versus NEMBUTAL.
BUTALAN vs NEMBUTAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butalan is an ergot alkaloid derivative that acts as a partial agonist at serotonin (5-HT2B) receptors and an antagonist at alpha-adrenergic and dopamine (D2) receptors. It also inhibits prolactin secretion by stimulating dopamine receptors in the pituitary.
Barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and neuronal hyperpolarization. At high doses, has direct inhibitory effects on excitatory AMPA and kainate receptors.
1-2 tablets (50-100 mg butalbital, 325-650 mg acetaminophen, 40 mg caffeine) orally every 4 hours as needed, not exceeding 6 tablets per day.
Induction of anesthesia: 50-120 mg IV as a single dose. Maintenance of anesthesia: additional doses of 20-40 mg IV as needed. For sedation (preoperative): 100-200 mg IM or 1-5 mg/kg IV 1-1.5 hours before procedure. For status epilepticus: loading dose of 5-15 mg/kg IV slow push, then 1-5 mg/kg/h IV infusion.
None Documented
None Documented
4-6 hours (terminal); prolonged in renal impairment (up to 12-15 hours)
Terminal elimination half-life is 40-120 hours (mean ~80 hours). The prolonged half-life contributes to accumulation with repeated dosing and residual sedation.
Primarily renal (70% unchanged, 20% as metabolites); fecal 10%
Renal elimination of unchanged drug accounts for approximately 30-35% of a dose; the remainder is hepatically metabolized. Less than 5% is excreted unchanged in feces.
Category C
Category C
Barbiturate
Barbiturate